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Title: The impact of vaginal laser treatment for genitourinary syndrome of the menopause 
in breast cancer survivors: a systematic review and meta-analysis 
Abstract (250 words) 
 
Introduction: Genitourinary syndrome of the menopause (GSM) is caused by hypo-
oestrogenism resulting in vaginal dryness, pain, dyspareunia and urinary tract infection.   It 
is more severe and common in breast cancer (BC) survivors due to the severity of induced 
menopause following treatment i.e. chemotherapy, GnRH agonists/ antioestrogen therapy.   
It has a detrimental effect on quality of life.   The gold standard therapy is topical oestrogen 
which is highly effective however is contraindicated in BC patients due to concerns with 
recurrence. Recently vaginal laser therapy has been used to restore vaginal mucosal 
thickness, lubrication and elasticity with good effect in menopausal women with GSM.  The 
aim of this study is to assess the impact of vaginal laser therapy on breast cancer associated 
GSM.  
Methods: A systematic review and meta-analysis. 
Results:   48 papers were identified revealing 10 observational studies of GSM symptoms 
before and after vaginal laser therapy with no randomised trials.    
Vaginal laser was effective in treating GSM in BC survivors with improvement in vaginal 
health index, Visual Analogue Scale score for dyspareunia and vaginal dryness, sexual 
function and overall satisfaction in the short term with minimal adverse events.  
Conclusion:  Vaginal laser may be effective in treating GSM in BC survivors in the short term 
but there is no long term data of safety and efficacy.   
More research is needed looking at longer term follow up, health economic costs and sub 
group analysis as well as the complex interplay between GSM and the other negative 
impacts of BC therapy on intimate relationships. 
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Background 
Breast cancer is the most commonly diagnosed cancer in women and each year in the UK 
50,000 women are diagnosed with the condition. Up to 25% of women develop BC pre-
menopausally and many of these women will undergo treatment induced premature 
menopause1.   Many more breast cancer patients who are already post-menopausal at 
diagnosis will suffer a worsening of menopausal symptoms due to prolonged antioestrogen 
therapies (tamoxifen or an aromatase inhibitor for 5 or, increasingly 10 years).  As survival 
rates at 5 years are now ~90%2, there are many millions of breast cancer survivors globally, 
many of whom have their quality of life significantly impaired by ongoing menopausal 
symptoms.      
One of the most distressing symptoms of menopause is genitourinary syndrome of the 
menopause (GSM) 3.   Genitourinary syndrome of the menopause is due to lack of 
oestrogenic stimulus to the vulva and vagina, causing atrophy of the vaginal wall, loss of 
elasticity, loss of the normal moisture and pH balance.  This results in pain, irritation, 
burning, vaginal discharge, dyspareunia, repeated urinary tract infections and may 
significantly impact on intimate relations with their partner.      
GSM affects 20-50% of women after the menopause 4-6. In breast cancer patients, who 
undergo menopause at an accelerated rate (e.g., drug-induced such as with chemotherapy, 
or use of chemical ovarian suppression with GnRH agonists), or undergo a more severe 
degree of hypo-oestrogenic state due to use of aromatase inhibitor therapy, symptoms of 
GSM can occur sooner and be more severe than is found among those with a normal, paced 
menopause 7-9.  Symptoms are often not disclosed by patients due to embarrassment. It has 
an adverse emotional and physical impact on women and can be detrimental to 
relationships through unsatisfactory sexual relationships 10.  A premature menopause in 
young breast cancer patients (e.g., less than 40 years of age) can have a profoundly negative 
impact on quality of life secondary to sexuality and intimacy changes 11. Women of all ages 
wish to preserve their sexual function and improve their sexual quality of life 12;13. Thus, 
GSM impacts women of all ages as a survivorship issue.  
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Unlike the vasomotor symptoms of the menopause which settle with time, GSM worsens 
with time and is unlikely to resolve without intervention8;14. The diagnosis of GSM is 
confirmed through patient-reported symptoms and gynaecological examination of external 
structures, introitus, and vaginal mucosa. Lifestyle modifications can be helpful but are 
insufficient to significantly improve symptoms and non-hormonal vaginal therapies may 
provide some relief by reducing vaginal dryness. However the single treatment which would 
alleviate symptoms i.e. oestrogen, is contraindicated in breast cancer survivors.  Systemic 
hormone replacement therapy may have an adverse effect of breast cancer survival (HABITs 
Trial) and is contraindicated.  However there is little data about the breast cancer 
recurrence risk associated with use of topical antioestrogen creams, with several small 
series showing no adverse effect on breast cancer but a marked improvement in GSM.   
However, women and their clinicians are rarely comfortable using topical oestrogens in the 
post breast cancer setting.   
In recent years 2 types of laser therapy, microablative fractional CO2 (SmartXide2 V2 LR, 
Monalisa Touch, DEKA, Florence, Italy) and non-ablative photothermal Erbium: Yag-laser (Er: 
Yag-laser) (Fotona SmoothTM XS, Fotona, Ljubljana Slovenia) have been used in 
postmenopausal women with GSM.   This has the advantage of being non hormonal and 
therefore carries no risk of worsening breast cancer survival outcomes. They have been 
shown to be equivalent in efficacy 15.  In the non-breast cancer setting, GSM in women who 
have undergone a normal menopause is significantly improved and the treatment seems to 
have equivalence to use of topical oestrogen, the gold standard16.  
The treatment works by inducing collagen remodelling and increased vascularization in ex-
vivo studies 17. Its microablative effects improve vaginal health by restoring vaginal flora to 
the premenopausal state with predominant lactobacilli 18. These effects are long lasting, 
persisting up to 1-year follow-up 19.   However the efficacy in women made iatrogenically 
menopausal by their cancer treatment has not been widely or rigorously studied.  GSM in 
this setting may be relatively more refractory to therapy.   The purpose of this systematic 
review is to assess the impact of vaginal laser therapy on breast cancer associated GSM. 
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Materials and Methods 
This systematic review of the literature followed the MOOSE guidelines for the reporting of 
meta-analysis of Observational studies 20.  It was registered prospectively on the PROSPERO 
database (registration number: CRD42018089610). 
Eligibility criteria, search strategy, and data extraction 
Ovid Medline (1996-, March 2018), Embase, Pubmed, Cochrane register of controlled trials 
(CCTR), Cochrane database of systematic reviews (CDSR), CINAHL and Google scholar were 
searched for studies that analysed the effect of Vaginal Laser treatment on women with GSM 
in breast cancer survivors using medical subject heading (MeSH) themes. For each database 
a range of search strategies were performed.  A manual search of reference lists of all known 
and included studies was conducted to identify studies not captured by electronic searches 
to ensure complete coverage of literature. Conference abstracts were included if data could 
be extracted. Unpublished work was excluded. No language restrictions were applied. The 
title and abstracts were screened by two independent reviewers (SJ and PK).  Full articles of 
all citations that were likely to meet the predefined selection criteria were obtained. Data was 
extracted independently by two authors (SJ and PK) and recorded on a data collection form.  
Any discrepancies were settled by discussion with the senior author (LW). The search output 
is shown in Figure 1. 
A protocol was developed with explicitly defined objectives, criteria for selection and quality 
assessment of studies, primary and secondary outcomes and statistical methods. The 
following data were extracted: first author, year of publication, type of laser used, 
therapeutic protocol, duration of follow up, baseline characteristics of participants, the 
symptoms of GSM being analysed, the tools used for assessment, any objective 
measurements of vaginal pathophysiology, adverse events and drop outs due to these 
effects. All studies included in the systematic review are shown in Table 1. 
Study selection 
The study population included women with breast cancer who had completed preliminary 
treatment for their cancer and suffered from GSM as a consequence. Any study which 
assessed the effect of vaginal laser treatment on GSM in this cohort of women were 
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included. Where data were incomplete the authors were contacted by email and if no 
response was received after 2 weeks, a further email was sent.    
Methodological quality assessment 
The risk of bias assessment based on the quality of the studies was performed using the 
Modified Newcastle Ottawa Scale (NOS). The NOS is a scale designed to assess the quality of 
non-randomized epidemiologic research. Stars are aƐƐŝŐŶĞĚĨŽƌĂƐƚƵĚǇ ?ƐĚĞƐŝŐŶ
characteristics. Studies that garner more stars are deemed to be of higher quality. Using the 
tool, each study is judged on six items, categorized into three groups: the selection of the 
study groups; the comparability of the groups; and the ascertainment of either the outcome 
of interest. Stars awarded for each quality item serve as a quick visual assessment. Stars are 
awarded such that the highest quality studies are awarded up to 9 stars.  
Quality assessment of all studies included in the review is shown in Table 2.  
Data extraction and Synthesis 
The meta-analysis was performed using Review Manager 5.3 (RevMan). This was performed 
if more than 3 studies reported on data.  Heterogeneity was assessed by examining the 
characteristics of the included studies. The outcomes included in the meta-analysis included 
the vaginal health index (VHI), a visual analogue scale (VAS) for dyspareunia and the Female 
Sexual Function Index (FSFI). Overall improvement in symptoms was reported and estimated 
for the different studies.  For continuous variables inverse variance estimates were used with 
a random effects model to calculate mean values and 95% confidence intervals.  For 
categorical variables Mantel-Haenszel estimates were used with a random effects model to 
calculate odds ratios and their 95% confidence intervals (CIs).  
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Results 
Study Selection 
The search strategy revealed 48 references which were assessed for eligibility.  38 studies 
were excluded.  10 studies involving 522 women undergoing vaginal laser treatment following 
breast neoplasia treatment were considered eligible and were included in this systematic 
review: all were cohort studies as there have been no randomised trials to date. The search 
strategy is summarized in Figure 1 and details of studies included are in Table 1. 
Study Characteristics 
Ten studies were identified as being suitable for inclusion. Five were observational studies 
and the remaining five were conference abstracts with limited data. Of these studies, 7 used 
the CO2 Laser and 3 used the Erbium YAG. All studies were observational cohort studies 
reporting on the effects of laser treatment before and after completion of treatment on the 
same cohort of patients. The time elapsed since the last laser treatment was the follow up 
interval and varied from 4 weeks to 24 months. There was one study which duplicated data 
so was excluded from the analysis. There were no randomised controlled trials. The treatment 
protocol varied in the different studies ranging from 3-5 treatment sessions in the CO2 laser 
treatment and 1-3 in the Erbium YAG laser treatments.  
There was significant heterogeneity of the studies with respect to women undergoing the 
laser treatment. The time elapsed since the completion of active treatment for breast 
cancer varied and the age of the participants as well as time elapsed since the menopause 
was variable. Most studies did not comment on the type of endocrine therapies the patients 
were on. In all studies outcomes were reported before and after laser treatment.  
Risk of Bias of Included Studies  
 The Newcastle Ottawa Scale (NOS) was used to assess the quality of studies. A 'star system' 
has been developed in which a study is judged on three broad perspectives: the selection of 
the study groups; the comparability of the groups; and the ascertainment of either the 
exposure or outcome of interest. This scale has been adapted from the Newcastle-Ottawa 
Quality Assessment Scale for cohort and case-control studies to perform a quality 
assessment of cross-sectional studies for the purposes of this systematic review.   This 
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modified scale has been used by several other studies that have felt the need to adapt the 
NOS scale so as to appropriately assess the quality of cross-sectional studies 21.  
The risk of bias assessments are summarized in Table 2.  
Synthesis of Results 
A meta-analysis was undertaken for all outcomes that were represented in more than 3 
studies. 7 studies analysed the VHI, 4 studies the VAS for dyspareunia, 5 studies VAS for 
vaginal dryness.  3 studies reported on the FSFI and 6 studies reported on satisfaction/ 
improvement rates.  
Vaginal Health Index: 7 studies reported on Vaginal health index, all of which reported an 
improvement but only 5 22-26 were used for the meta-analysis as they gave pre and post 
treatment scores. There was a significant improvement in VHI scores post treatment (mean 
difference -11.35; 95% CI -11.76, -10.94). Two further studies 27;28 reported a significant 
improvement (p< 0.01) but could not be used for the meta-analysis as the individual scores 
pre and post treatment were not provided.  
Results are shown in Figure 2. 
Visual Analogue Scale (VAS) Dyspareunia: 4 studies were used for this analysis 22;24;29;30 all of 
which showed an improvement (Mean Difference 2.22; 95% CI 1.98, 2.46).  
Results are shown in Figure 3 
Visual Analogue scale (VAS) Dryness: 5 studies were used for this analysis 22;24;29-31all of 
which showed an improvement (Mean Difference 2.72; 95% CI 2.50, 2.93).  
Results are shown in figure 4.  
Sexual Function: 3 Studies 23;27;29 used the Female Sexual Function Index (FSFI) to assess 
sexual function before and after treatment and all studies showed an improvement in 
sexual function.  
Overall satisfaction: 83.53 % of patients undergoing treatment experienced 
improvement/satisfaction following treatment (Table 3). 
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Adverse events 
Nine studies reported no adverse effects from treatment. Pagano 30 reported adverse 
effects in three out of 82 patients who discontinued treatment due to discomfort after 2 
cycles.  
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Conclusion  
Principal findings: 
This systematic review shows that vaginal Laser treatment may result in objective and 
symptomatic improvement in vaginal health in BC survivors in the short term. There 
appeared to be an improvement in VHI and the VAS scores for dyspareunia and vaginal 
dryness following treatment. Sexual function appeared to improve and overall satisfaction 
was in excess of 80%. Very few adverse events were reported.   These included transient 
irritation and discharge which was generally mild and self-limiting.  The procedure was well 
tolerated with few patients unable to complete the course of treatment.   The duration of 
effect was however mainly limited to short term follow up (4 weeks to 12 weeks) with 1 
study reporting on 24 months outcomes.   There are no reports of major long term 
complications such as vaginal stenosis or ulceration, but patient follow up was limited. 
The majority of women included in these studies were on some form of antioestrogen 
therapy, either tamoxifen or an aromatase inhibitor.   Aromatase inhibitors are linked to 
more marked vaginal changes than tamoxifen, which has a partial oestrogen agonist effect 
on gynaecological tissues whereas the AIs reduce circulating oestrogen levels to almost 
undetectable levels.   It was not possible to undertake subgroup analysis to assess whether 
vaginal laser is equally effective in both groups of women. 
To date, no randomised controlled trials comparing topical oestrogen cream with vaginal 
laser has been undertaken in BC survivors. The feasibility of conducting such a trial needs to 
be explored.   However such studies have been performed in the non-breast cancer/normal 
menopausal setting and have shown equivalent efficacy. 
Strengths and weaknesses of the study: 
There are several limitations to this systematic review and these relate to the lack of robust 
studies or well conducted trials which could be included in the review. Though the data 
from this review and meta-analysis support the use of vaginal laser therapy in the post 
breast cancer setting for GSM, more data is needed about longevity of effect and cost 
effectiveness before this can be implemented in clinical practice. 
None of the studies included in the systematic review were randomised control trials and 
blinding of results was not performed in any of the studies. Five of the ten studies were 
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conference abstracts with limited data available. Follow up was limited to the short term 
with only one study reporting on 24 month outcomes 32.  In addition none of the studies 
carried out a formal sample size calculation therefore it is difficult to know if the studies 
were adequately powered to answer the research question.  
Lastly, none of the studies included in this review examined in detail the complex 
underpinnings of sexual dysfunction post breast cancer.  Genitourinary syndrome of the 
menopause will have a significant negative impact on sexual intimacy for these women and 
their partners, but breast cancer affects sexuality and relationships much more widely with 
lack of confidence, body image concerns, fatigue and depression all contributing.   Dealing 
with the GSM for these women and their partners may help them to restore their intimate 
relationship but may not, in isolation, be enough to restore them to their pre breast cancer 
state.    
Strengths and Weaknesses related to other studies: 
Pitsouni 33 and Salvatore 34 carried out a systematic review of vaginal laser treatment in 
menopausal women with GSM in the absence of a diagnosis of BC. In their reviews, the 
number of patients included was greater and the outcomes amenable to a meta-analysis 
included sexual function, vaginal maturation index (VMI), and urinary symptoms including 
urinary incontinence and burning. They also carried out a subgroup analysis of CO2  laser 
which was not possible with our review. Similar to our review, both these studies showed an 
overall improvement in all parameters with minimal adverse events reported.  
None of the studies report consensus on the number of treatment sessions recommended. 
In addition there are no studies comparing the 2 types of vaginal laser.  
Future Research 
More research is needed to assess the wider impact on different breast cancer survivor 
subgroups (age, degree of GSM, and type of antioestrogen therapy) and to assess the health 
economic impact of therapy before it can be made available more widely. Vaginal Laser 
therapy may have the potential to improve the quality of life for the many breast cancer 
survivors who struggle with GSM, however there are no studies with long term follow up 
hence this should not be introduced into clinical practice till more robust evidence is 
available.  
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There are currently no studies comparing the two types of laser, CO2 and Erb: Yag to 
establish if one is better than the other, though there appears to be equivalence. There is 
also no consensus on the number of treatments required for the different types of laser, 
need for repeat and top up treatments or adverse events in women undergoing top up 
treatments and research into all aspects of treatment is urgently required. A study using 
Erbium laser found that the positive effects were maintained for up to 12-18 months after 
completion of treatment but may require repeat treatment as it is not a definitive cure of 
GSM.  
A randomised trial to compare laser with no treatment or with topical oestrogen in this 
group of patients, with subgroup analysis for different degrees of severity and with a 
detailed assessment of the psychological and quality of life impacts is urgently needed. 
Detailed assessment of the health economic costs is needed to enable health funders to 
assess whether this technique is likely to be cost effective. 
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Clinical Practice points  
Vaginal laser therapy may be effective at improving the symptoms of GSM in women with a past 
history of breast cancer with a potential response in the short term.  This may be a useful, non-
hormonal method of ameliorating this distressing symptom complex for breast cancer survivors. 
However patients need to be informed of the lack of long term data on the procedure particularly 
after the recent FDA35 guidance pertaining to vaginal rejuvenation. Laser treatment would be a last 
resort and only where other modalities have failed.  
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    Description of any contact with authors Yes 6 
Reporting of methods should include:       
    Description of relevance or appropriateness of studies assembled for assessing the 
hypothesis to be tested 
Yes 8 
    Rationale for the selection and coding of data (eg, sound clinical principles or 
convenience) 
Yes 8 
    Documentation of how data were classified and coded (eg, multiple raters, blinding, 
and interrater reliability) 
Yes 8 
    Assessment of confounding (eg, comparability of cases and controls in studies where 
appropriate) 
Yes 8 
    Assessment of study quality, including blinding of quality assessors; stratification or 
regression on possible predictors of study results 
Yes 7 
    Assessment of heterogeneity Yes 7 
    Description of statistical methods (eg, complete description of fixed or random 
effects models, justification of whether the chosen models account for predictors of 
study results, dose-response models, or cumulative meta-analysis) in sufficient detail 
to be replicated 
Yes 7 
    Provision of appropriate tables and graphics Yes Attache
d 
Tables 
and 
Figures 
Reporting of results should include:   
   Graphic summarizing individual study estimates and overall estimate Yes Table 1 
   Table giving descriptive information for each study included Yes Table 1 
    Results of sensitivity testing ( eg, subgroup analysis) No NA 
    Indication of statistical uncertainty of findings No NA 
Reporting of discussion should include:   
    Quantitative assessment of bias (eg, publication bias) No NA 
    Justification of exclusion (eg, exclusion of non-English-language citations) Yes Figure 1 
    Assessment of quality of included studies Yes Table 2 
Reporting of conclusions should include:   
    Consideration of alternative explanations for observed results Yes 11 
    Generalization of the conclusions (ie, appropriate for the data presented and within 
the domain of the literature review) 
Yes 13 
    Guidelines for future research Yes 13 
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    Disclosure of funding source Yes 1 
 
Figure 1: Study selection criteria 
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Table 1.  Summary of included studies 
 
Study 
Reference 
Locatio
n 
No of 
treatme
nt 
Cycles 
No of 
Patien
ts 
Avera
ge age 
of 
patien
ts 
Time 
period 
Follow 
Up 
Period 
Outcom
es 
Type of 
Laser 
Becorpi 
(2017)23 
Florenc
e, Italy 
2 20 58.2 Decemb
er 2015-
February 
2015 
4 weeks 
post 
final 
treatme
nt 
VHI, 
FSFI, 
VAS 
CO2 
Microablati
ve 
Gamabacci
ani (2017)22 
  
Pisa, 
Italy 
3 37 50.8 Not 
Stated 
24 
months 
post 
final 
treatme
nt 
VHI,VAS Erbium 
YAG 
Guerette 
(2017)29 
Virginia
, US 
3 57 49.6 July 
2017-
Decemb
er 2017 
4 weeks 
post 
final 
treatme
nt 
FSFI, 
VAS 
Erbium 
YAG 
Joris 
(2015)24 
Brussel
s, 
Belgiu
m 
3  7 - January 
2014-
July 
2014 
30 days 
post 
final 
treatme
nt 
VHI, 
VAS, 
VMI  
CO2 
Microablati
ve 
Maggiori 
(2015)27 
 
Milan, 
Italy 
5  40 - Not 
Stated 
4 weeks 
post 
final 
treatme
nt 
VHI, 
FSFI, 
QoL 
(SF12)  
CO2 
Microablati
ve 
Mothes 
(2018)25 
Jena, 
Germa
ny 
1 16 71 Septemb
er 2016-
June 
2017 
6 weeks 
post 
final 
treatme
nt 
VHI Erbium 
YAG 
Pagano 
(2018)30  
Naples, 
Italy 
3 82 44 April 
2015- 
May 
2017 
30 days 
post 
final 
treatme
nt 
VAS CO2 
Microablati
ve 
Pearson 
(2017)31 
Sydney
, 
Australi
a 
3 25 55 February 
2016-
May 
2017 
4 weeks 
post 
final 
treatme
nt 
VAS  CO2 
Microablati
ve 
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Pieralli 
(2016)26  
Florenc
e, Italy 
3  50 53.3 June 
2013- 
June 
2015 
11 
months 
post 
final 
treatme
nt  
VHI, 
VAS 
CO2 
Microablati
ve 
Scibilia 
(2017)28 
Catania
, Italy 
3 20 - Not 
Stated 
3 
months 
post 
final 
treatme
nt 
VHI, 
VAS, 
ICIQ 
 
CO2 
Microablati
ve 
 
 
 
 
Table 2.  Summary of the quality of included studies for risk of Bias (Newcastle Ottawa Scale) 
 
  Selection (5 stars) Comparability 
(2 Stars) 
Outcom
(3 Stars
Represent
ation 
* 
Sample Size 
* 
Ascertainment 
of Exposure 
** 
Non 
Respondents 
* 
Comparability 
** 
Assessment 
of outcome 
** 
Statistical 
Becorpi (2017)  
  
* - ** - ** - 
Gamabacciani 
(2017) 
  
* * ** - ** ** 
Guerette (2017) * * * - * * 
Joris  (2015) 
 
* - * - * * 
Maggiori(2015) * * * - * ** 
Mothes (2018) * - ** - * ** 
Pagano (2018) * * ** - ** ** 
Pearson (2017) * - * - * ** 
Pieralli (2016) * * 
 
** - ** ** 
Scibilia (2017) * - * _ - * 
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Table 3.  Table showing the percentage Improvement in symptoms or satisfaction following 
vaginal laser therapy.    
 
Study Percentage improvement/satisfaction  
Gambacciani (2017) 96.1 
Maggiori (2015) 77.5 
Mothes (2018) 93.7 
Pearson ( 2017) 85 
Pieralli (2016) 58.9 
Sciblia (2017) 90 
 
 
Figure 2: Vaginal Health Index (VHI) 
 
 
Forest plots show improvement in the Vaginal health index following vaginal laser treatment.  
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Figure 3: VAS: Dyspareunia 
 
 
 
Forest plots show improvement in the Dyspareunia following vaginal laser treatment.  
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